Genentech ( DNA) is being victimized by paranoid traders who fail to see that it had a great quarter, Jim Cramer said on CNBC's "Stop Trading!" segment Wednesday. "They're way too quick to pull the sell trigger here," Cramer said, noting that a similar failure of nerve plagued Alcoa ( AA) after it reported a record quarter on Monday. "Alcoa came back. I bet you Genentech bounces back," he said. "This was not a preannouncement to the downside like at EMC. This was a good quarter," Cramer said. What do Alcoa and Genentech have in common? "They're not expensive." Cramer was also bullish on Genzyme ( GENZ), saying it could go back to $70 after posting an "excellent" quarter Tuesday morning. Genzyme has been hurt by concerns that biotech company Amicus Therapeutics had therapies that would compete with Genzyme's drugs. But Amicus recently filed an early prospectus for its initial offering and "it turns out that they aren't really that competitive," Cramer said. Cramer said a weak outlook from Brunswick ( BC) was sowing more concerns about high-end goods makers. "The problem is that when you add the big-screen TV problem that we got from 3M to the boat problem at Brunswick, people get the sense that wealthier consumers are pulling back," Cramer said.